CELC — Celcuity Inc.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1603454 ·
Last close
$86.38
Market Cap
$4.21B
52W High
$151.02
52W Low
$78.60
ADV30
1,649,690
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -50,507,000 | -52,841,000 | 410,164,000 | 145,191,000 | 356,639,000 |
| Dec 2025 | 0 | — | -49,201,000 | -50,973,000 | 466,558,000 | 165,703,000 | 366,003,000 |
| Sep 2025 | 0 | — | -42,849,000 | -43,804,000 | 476,004,000 | 74,252,000 | 359,041,000 |
| Jun 2025 | 0 | — | -44,009,000 | -45,268,000 | 183,592,000 | 46,354,000 | 139,217,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-172,492,000
Investing CF
$-53,827,000
Financing CF
$355,032,000
CapEx
$-474,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.90
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-501,738,000
Inventory
—
Receivables
$1,600,621
ST Investments
$241,873,000
EBIT TTM
$-172,836,000
Pretax Income TTM
$-192,886,000
Interest Exp TTM
$20,050,000
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -172,192,000 | -177,042,000 | 466,558,000 | 366,003,000 | — | -153,280,000 |
| Dec 2024 | 0 | -113,267,000 | -111,779,000 | 245,123,000 | 129,504,000 | — | -83,467,000 |
| Dec 2023 | 0 | -66,230,331 | -63,779,116 | 191,219,398 | 51,450,076 | — | -53,812,253 |
| Dec 2022 | 0 | -39,391,091 | -40,370,040 | 175,697,097 | 41,925,630 | — | -36,008,171 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.96
Max Pain — expiry 2026-08-21
max pain strike: $90.00 · spot: $86.38 · call oi: 2,638 · put oi: 4,666
Expected Move to 2026-08-21:
±$11.95
(13.83%) —
implied range
$74.43 –
$98.33
· ATM straddle on $85.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CON | Concentra Group Holdings Parent, Inc. | $4.05B | $31.65 | — |
| CAI | Caris Life Sciences, Inc. | $4.43B | $15.67 | — |
| LFST | LifeStance Health Group, Inc. | $4.00B | $10.48 | — |
| VCYT | VERACYTE, INC. | $3.70B | $46.32 | — |
| RDNT | RadNet, Inc. | $5.02B | $63.78 | — |
News headlines (Yahoo Finance, 1h cache)
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
2026-07-30 12:30 · Yahoo
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
2026-07-15 20:16 · Yahoo
Celcuity gains FDA approval for closely watched breast cancer drug
2026-07-15 12:18 · Yahoo
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer
2026-07-15 08:02 · Yahoo
CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug
2026-07-14 21:24 · Yahoo
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
2026-07-14 20:53 · Yahoo
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
2026-06-19 12:24 · Yahoo
Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offering
2026-06-04 19:11 · Yahoo
Celcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients
2026-06-04 09:07 · Yahoo
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
2026-06-04 02:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.